Clinical Trial Update: IFx-Hu2.0 for the Treatment of Patients With Skin Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial of IFx-Hu2.0 for skin cancers has completed with results posted. The study evaluated IFx-Hu2.0 in patients with Cutaneous Squamous Cell Carcinoma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma
• Cutaneous Squamous Cell Carcinoma

Drugs mentioned

• IFx-Hu2.0

Snippet

Sponsor: TuHURA Biosciences, Inc. | Conditions: Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma | Phase 1 | Status: COMPLETED | Results posted: 2024-08-02